A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2026-01-30
Target enrollment:
Participant gender:
Summary
This clinical trial is evaluating a drug called AC176 in Chinese participants with metastatic
castration resistant prostate cancer (mCRPC) who have progressed on at least one prior
systemic therapy.
The main goals of this study are to:
Evaluate the safety and tolerability of AC176, evaluate pharmacokinetics and preliminary
antitumor activity of AC176